Q5118 HCPCS code: Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg
Q5118 is the HCPCS Level II code for injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg. In 2024 Medicare paid an average of $16.35 per service for Q5118 across 1,219,678 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 230 per day on outpatient hospital claims. Medicare volume fell 51% from 2022 to 2024 (2,488,492 to 1,219,678 services). In 2024, about 2,114 clinicians billed Medicare for Q5118 for 3,305 beneficiaries; California, Texas, Florida accounted for 44% of services.
Code details
| Field | Value |
|---|---|
| Section | Q codes — Temporary codes |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2019-10-01 |
| Last action effective | 2019-10-01 |
Who bills Q5118 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 2,114 |
| Medicare beneficiaries | 3,305 |
| States with claims | 30 |
| Share of services in top 3 states (California, Texas, Florida) | 44% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for Q5118, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 2,488,492 | 5,623 | $42.79 | $34.16 |
| 2023 | 2,329,893 | 5,670 | $29.16 | $23.22 |
| 2024 | 1,219,678 | 3,305 | $20.54 | $16.35 |
States with the most Q5118 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| California | 201,204 | $16.47 |
| Texas | 199,734 | $16.44 |
| Florida | 122,197 | $16.36 |
| Illinois | 82,984 | $16.73 |
| Virginia | 80,372 | $16.64 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 230 | CMS Policy |
| practitioner claims | 230 | CMS Policy |
Medicare policy articles for this code
- A52370: Billing and Coding: Bevacizumab and biosimilars (Wellpoint Federal (MAC - Part A, MAC - Part B))
Covered diagnoses (458 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| C17.0 | Malignant neoplasm of duodenum | 1 |
| C17.1 | Malignant neoplasm of jejunum | 1 |
| C17.2 | Malignant neoplasm of ileum | 1 |
| C17.3 | Meckel's diverticulum, malignant | 1 |
| C17.8 | Malignant neoplasm of overlapping sites of small intestine | 1 |
| C17.9 | Malignant neoplasm of small intestine, unspecified | 1 |
| C18.0 | Malignant neoplasm of cecum | 1 |
| C18.1 | Malignant neoplasm of appendix | 1 |
| C18.2 | Malignant neoplasm of ascending colon | 1 |
| C18.3 | Malignant neoplasm of hepatic flexure | 1 |
Showing 10 of 458. The full list, non-covered diagnoses and CSV export are in Caduvo.
What changed for Q5118
- 2019-10-01: Q5118 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code Q5118?
Q5118 is the HCPCS Level II code for injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg. Short descriptor: "Inj., zirabev, 10 mg".
How much does Medicare pay for Q5118?
In 2024, the average Medicare payment was $16.35 per service (average allowed $20.54).
Does Medicare cover Q5118?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Which diagnoses support coverage for Q5118?
Medicare policy articles that cite Q5118 list 458 covered ICD-10-CM diagnosis codes across 1 article. The most cited include C17.0 (Malignant neoplasm of duodenum), C17.1 (Malignant neoplasm of jejunum), C17.2 (Malignant neoplasm of ileum). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of Q5118 can be billed per day?
230 on outpatient hospital claims; 230 on practitioner claims (NCCI medically unlikely edits).
Related Q51 codes
- Q5100 — Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg
- Q5101 — Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram
- Q5102 — Injection, infliximab, biosimilar, 10 mg
- Q5103 — Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg
- Q5104 — Injection, infliximab-abda, biosimilar, (renflexis), 10 mg
- Q5105 — Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units
- Q5106 — Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units
- Q5107 — Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
- Q5108 — Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
- Q5109 — Injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg
- Q5110 — Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
- Q5111 — Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under Q5118
- Watch Q5118 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for Q5118
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.